Currently we test and support the following browsers:
Please note that this is not intended to be an exhaustive list of browsers that support web standards, nor a test of browser compliance, nor a side-by-side comparison of various manufacturers’ browsers.
Member, St. Jude Faculty
Arthur Ashe Chair in Pediatric AIDS Research
Director, Clinical Research, Infectious Diseases
Director, Translational Trials Unit
Co-Leader, HIV Therapeutics & Vaccine Development, CIDC
Patricia Flynn, MD
MS 600, Room Q1114
St. Jude Children's Research Hospital
262 Danny Thomas Place
Memphis, TN 38105-3678
Phone: (901) 595-2338
FAX: (901) 595-5068
BS - Rhodes College (formerly Southwestern at Memphis), Memphis, Tennessee (1977)
MS - Epidemiology, University of Tennessee, Memphis, College of Graduate Health (2002)
MD - Louisiana State University Medical Center, New Orleans, Louisiana (1981)
Flynn PM, Nachman S, Muresan P, Fenton T, Spector SA, Cunningham CK, Pass R, Yogev R, Burchett S, Heckman B, Bloom A, Utech LJ, Anthony P, Petzold E, Levy W, Siberry GK, Ebiasah R, Miller J, Handelsman E, Weinberg A; for the IMPAACT P1088 Team. Safety and immunogenicity of 2009 pandemic H1N1 influenza vaccination in perinatally HIV-1-infected children, adolescents, and young adults. J Infect Dis July 3, 2012.
Havens PL, Stephensen CB, Hazra R, Flynn PM, Wilson CM, Rutledge B, Bethel J, Pan CG, Woodhouse LR, Van Loan MD, Liu N, Lujan-Zilbermann J, Baker A, Kapogiannis BG, Mulligan K, the Adolescent Medicine Trials Network (ATN) for HIV/AIDS Interventions 063 study team. Vitamin D3 decreases parathyroid hormone in HIV-infected youth being treated with tenofovir: a randomized, placebo-controlled trial. Clin Infect Dis 54(7):1013-25, 2012.
Hakim H, Allison KJ, Van De Velde LA, Li Y, Flynn P, McCullers JA. Immunogenicity and safety of inactivated monovalent 2009 H1N1 influenza A vaccine in immunocompromised children and young adults. Vaccine December 8, 2011.
Carr S, Allison KJ, Van De Velde LA, Zhang K, English EY, Iverson A, Daw NC, Howard SC, Navid F, Rodriguez-Galindo C, Yang J, Adderson EE, McCullers JA, Flynn PM. Safety and immunogenicity of live attenuated and inactivated influenza vaccines in children with cancer. J Inf Dis 204(10):1475-1482, 2011.
Halasa N, Englund JA, Nachman S, Weinberg GA, Huber VC, Allison KJ, Dubovsky F, Yi T, McCullers JA, Flynn PM. Safety of live attenuated influenza vaccine in mild to moderately immunocompromised children with cancer. Vaccine 29(24):4110-4115, 2011.
Flynn PM, Mirochnick M, Shapiro DE, Bardeguez A, Rodman J, Robbins B, Huang S, Fiscus SA, Van Rompay KK, Rooney JF, Kearney B, Mofenson LM, Watts DH, Jean-Philippe P, Heckman B, Thorpe E Jr, Cotter A, Purswani M, PACTG 394 Study Team. Pharmacokinetics and safety of single dose tenofovir disoproxil fumarate and emtricitabine in HIV-1 infected pregnant women and their infants. Antimicrob Agents Chemother September 6, 2011.
Halasa N, Englund JA, Nachman S, Weinberg GA, Huber VC, Allison KJ, Dubovsky F, Yi T, McCullers JA, Flynn PM. Safety of live attenuated influenza vaccine in mild to moderately immunocompromised children with cancer. Vaccine 29(24):4110-5, 2011.
Garvie PA, Flynn PM, Belzer M, Britto P, Hu C, Graham B, Neely M, McSherry GD, Spector SA, Gaur AH, Pediatric AIDS Clinical Trials Group (PACTG) P1036B Team. Psychological factors, beliefs about medication, and adherence of youth with human immunodeficiency virus in a multisite directly observed therapy pilot study. J Adolesc Health 48(6):637-40, 2011.
Flynn PM, Cunningham CK, Rudy B, Wilson CM, Kapogiannis B, Worrell C, Bethel J, Monte D, Bojan KCN - for the Adolescent Medicine Trials Network for HIV/AIDS Interventions (ATN). Hepatitis B vaccination in HIV-infected youth: a randomized trial of three regimens. J Acquir Immune Defic Syndr 56(4):325-332, 2011.
Gaur AH, Belzer M, Britto P, Garvie PA, Hu C, Graham B, Neely M, McSherry G, Spector SA, Flynn PM. Directly observed therapy (DOT) for nonadherent HIV-infected youth: lessons learned, challenges ahead. AIDS Res Hum Retroviruses August 14, 2010.
Mehta N, Cunningham CK, Flynn P, Pepe J, Obaro S, Kapogiannis BG, Bethel J, Luzuriaga K. Impaired generation of hepatitis B virus-specific memory B cells in HIV infected individuals following vaccination. Vaccine 28(21):3672-3678, 2010.
Son M, Shapiro ED, Larussa P, Neu N, Michalik DE, Meglin M, Jurgrau A, Bitar W, Vasquez M, Flynn P, Gershon AA. Effectiveness of varicella vaccine in children infected with HIV. J Infect Dis May 4, 2010.
Adderson EE, Flynn PM, Hoffman JM. Efficacy and safety of cefepime in pediatric patients: a systematic review and meta-analysis. J Pediatr April 29, 2010.
McCullers JA, Van De Velde LA, Allison KJ, Branum KC, Webby RJ, Flynn PM. Recipients of vaccine against the 1976 "swine flu" have enhanced neutralization responses to the 2009 novel H1N1 influenza virus. Clin Infect Dis April 23, 2010.
Brown SA, Surman SL, Sealy R, Jones BG, Slobod KS, Branum K, Lockey TD, Howlett N, Freiden P, Flynn P, Hurwitz JL. Heterologous prime-boost HIV-1 vaccination regimens in pre-clinical and clinical trials. Viruses 2(2): 435-467, 2010.
Henry-Reid LM, O'Connor KG, Klein JD, Cooper E, Flynn P, Futterman DC. Current pediatrician practices in identifying high-risk behaviors of adolescents. Pediatrics 125(4):E741-E747, 2010.
Maron G, Gaur AH, Flynn PM. Antiretroviral therapy in HIV-infected infants and children. Pediatr Infect Dis J 29(4):360-363, 2010.
Cunningham CK, Rudy BJ, Xu J, Bethel J, Kapogiannis BG, Ahmad S, Wilson CM, Flynn PM, the Adolescent Medicine Trials Network for HIV/AIDS Interventions. Randomized trial to determine safety and immunogenicity of two strategies for hepatitis B vaccination in healthy urban adolescents in the United States. Pediatr Infect Dis J Feb 18, 2010.
Garvie PA, Lawford J, Gaur AH, Belzer M, McSherry GD, Hu C, Flynn PM, for the Pediatric AIDS Clinical Trials Group 1036A Study Team. Development of a Modified Directly Observed Therapy (MDOT) Adherence Intervention for Adolescents with HIV-1: Application of Focus Group Methodology to Inform Design, Feasibility and Acceptability. J Adolesc Health 44:124-132, 2009. (NIHMS92198).
Kiser JJ, Fletcher CV, Flynn PM, Cunningham CK, Wilson CM, Kapogiannis BG, Major-Wilson H, Viani RM, Liu NX, Muenz LR, Harris DR, Havens PL. Adolescent Trials Network for HIV/AIDS Interventions. Pharmacokinetics of antiretroviral regimens containing tenofovir disoproxil fumarate and atazanavir-ritonavir in adolescents and young adults with human immunodeficiency virus infection. Antimicrob Agents Chemother Feb;52(2):631-7, 2008. Epub 2007 Nov 19.
Kurt B, Flynn P, Shenep JL, Pounds S, Lensing S, Ribeiro RC, Pui CH, Razzouk BI, Rubnitz JE. Prophylactic antibiotics reduce morbidity due to septicemia during intensive treatment for pediatric acute myeloid leukemia. Cancer May 5, 2008. [Epub ahead of print]
Agwu A, Lindsey JC, Ferguson K, Zhang H, Spector S, Rudy BJ, Ray SC, Douglas SD, Flynn PM, Persaud D; and the Pediatric AIDS Clinical Trials Group 381 Study Team. Analyses of HIV-1 Drug-Resistance Profiles Among Infected Adolescents Experiencing Delayed Antiretroviral Treatment Switch After Initial Nonsuppressive Highly Active Antiretroviral Therapy. AIDS Patient Care STDS May 15, 2008. [Epub ahead of print].
McKinney RE Jr, Rodman J, Hu C, Britto P, Hughes M, Smith ME, Serchuck LK, Kraimer J, Ortiz AA, Flynn P, Yogev R, Spector S, Draper L, Tran P, Scites M, Dickover R, Weinberg A, Cunningham C, Abrams E, Blum MR, Chittick GE, Reynolds L, Rathore M. Long-term safety and efficacy of a once-daily regimen of emtricitabine, didanosine, and efavirenz in HIV-infected, therapy-naive children and adolescents: Pediatric AIDS Clinical Trials Group Protocol P1021. Pediatrics 120:e416–23, 2007.
Hope WW Seibel NL, Schwartz CL, Arrieta A, Flynn P, Shad A, Albano E, Keirns JJ, Buell DN, Gumbo T, Drusano GL, Walsh TJ. Population pharmacokinetics of micafungin in pediatric patients and implications for antifungal dosing. Antimicrob Agents Chemother 51:3714-3719, 2007.
Flynn PM, Rodman J, Lindsey JC, Robbins B, Capparelli E, Knapp KM, Rodriguez JF, McNamara J, Serchuck L, Heckman B, Martinez J, and the PACTG P1012 Team. Intracellular Pharmacokinetics of Once vs. Twice Daily Zidovudine and Lamivudine in Adolescents. Antimicrob Agents Chemother 51:3516-3522, 2007.
Flynn P, Havens P, Brady M. Emmanuel P, Read J, Hoyt L, Henry-Reid L, VanDyke R, Mofenson L. Male circumcision for prevention of HIV and other sexually transmitted diseases. Pediatr 119:821-22, 2007.
Flynn PM, Rudy BJ, Lindsey JC, Douglas SD, Lathey J, Spector SA, Martinez J, Silio M, Belzer M, Smith E, Hodge J, Hughes MD. Long-term observation of adolescents initiating HAART therapy: three year follow up. AIDS Res Hum Retroviruses Oct;23(10):1208-14, 2007.
Madden RM, Pui C-H, Flynn PM, Leung W. Prophylaxis of Pneumocystis carinii pneumonia with atovaquone in children with leukemia. Cancer 109:1654-8, 2007.
Zhou Z, Rodman JH, Flynn PM, et al. Model for intracellular lamivudine metabolism in peripheral blood mononuclear cellls ex vivo and in human immunodeficiency virus type-1 infected adolescents. Antimicrob Agents Chemother 50:2686-2694, 2006.
Rudy BJ, Lindsey JC, Flynn PM, Bosch RJ, Wilson CM, Hughes ME, Douglas SD and the PACTG Protocol 381 Study Team. Immune reconstitution and predictors of virologic failure in adolescnets infected through high risk behaviors and initiating HAART: week 60 results from the PACTG 381 cohort. AIDS Res Hum Retroviruses 22:213-21, 2006.
Denning DW, Marr KA, Lau WM, Facklam D, Ratanatharathorn V, Niederwieser D, Ullmann AJ, Seibel N, Flynn P, van Burik J, Buell DN, Patterson TF. Micafungin (FK463), Alone or in Combination With Other Systemic Antifungal Agents, for the Treatment of Acute Invasive Aspergillosis. J Infect 53:337-349, 2006.
Seibel NL, Schwartz C, Arrieta A, Flynn P, Shad A, Albano E, Keirns J, Lau WM, Facklam DP, Buell DN, Walsh TJ. Safety, tolerability, and pharmacokinetics of Micagunfin (FK463) in febrile, neutropenic pediatric patients. Antimicrob Agents Chemother 49:3317-24, 2005.
Miller, M, Obert, CA, Gao G, Daw, NC, Flynn P, Tuomanen E. High level cephalosporin-resistant pneumococci in patients with sickle cell disease. Emerg Infect Dis 11:1192-6, 2005.
Rutstein R, Gebo KA, Siberry GK, Flynn PM, Spector SA, Sharp VL, Fleishman JA. Hospital and outpatient health services utilization among HIV-infected children in care 2000-2001. Medical Care 43:III3-9, 2005.
Kadivar H, Garvie PA, Sinnock C, Heston JD, Flynn PM. Psychosocial profile of HIV-infected adolescents in a Southern US urban cohort. AIDS Care 18:544-9, 2006.
Chadwick EG, Rodman J, Britto P, Powell C, Palumbo P, Luzuriaga K, Hughes M, Abrams E, Flynn PM, Borkowsky W, Yogev R, and the PACTG Protocol 345 Team. Ritonavir-based highly active antiretroviral therapy in HIV-1 infected infants <24 months of age. Pediatr Infect Dis J 24:793-800, 2005.
Walsh TJ, Adamson PC, Seibel NL, Flynn PM, Neely MN, Schwartz C, Shad A, Kaplan S, Roden MM, Stone JA, Miller A, Bradshaw SK, Li SX, Sable CA, Kartonis NA. Pharmacokinetics, safety, and tolerability of caspofungin in children and adolescents. Antimicrob Agents Chemother 49:4536-45, 2005.
Rutstein RM, Gebo KA, Flynn PM, Fleishman JA, Sharp VL, Siberry GK, Spector SA. Immunologic function and virologic suppression among children with perinatally-acquired HIV-infected on HAART. Medical Care 43:III15-2, 2005.
Knapp KM, Flynn PM. Newer treatments for fungal infection. J Support Oncol 3:290-8, 2005.
Gaur AH, Flynn PM, Heine DJ, Giannini MA, Shenep JL, Hayden RT. Diagnosis of catheter-related bloodstream infection among pediatric oncology patients lacking a peripheral culture, using differential time to detection. Pediatr Infect Dis J 24:445-9, 2005.
Last update: July 2012